Pollogen

Company Overview

Snapshot

Founded in June 2006 by Zion Azar, Pollogen operates with 51–200 employees. The company was acquired by Lumenis in November 2015, marking a significant milestone in its journey.

Business overview

Pollogen develops and manufactures non-invasive, minimally invasive, and non-surgical solutions for medical aesthetics professionals. The company's core technology addresses various skin concerns including acne scars, cellulite reduction, facial contouring, skin rejuvenation, and wrinkle reduction. Pollogen serves the health tech and life sciences sector, specifically targeting medical devices and cosmetic materials within the healthcare and consumer markets.

Strategic signal

In August 2019, Pollogen's TriPollar Stop home-use device received FDA clearance. This regulatory approval validates the safety and efficacy of Pollogen's technology for at-home use, signaling a potential for broader market penetration and increased consumer trust in its beauty device offerings.

Company Intelligence Q&A

What is Pollogen's primary focus?

Pollogen focuses on providing safe, effective, and painless solutions for medical aesthetics professionals, specializing in non-invasive, minimally invasive, and non-surgical treatments for various skin conditions.

When was Pollogen acquired and by whom?

Pollogen was acquired by Lumenis in November 2015.

Which of Pollogen's products received FDA clearance?

In August 2019, Pollogen's leading home-use device, TriPollar Stop, received FDA clearance.

What are some of the technologies developed by Pollogen?

Pollogen develops and manufactures technologies under brand names such as OxyGeneo, Hybrid Energy, VoluDerm, TriPollar, TriLipo, TriFractional, and Stop V.

What was the focus of Pollogen's portfolio expansion in November 2016?

In November 2016, Pollogen, a Lumenis-owned company, expanded its portfolio with the Divine Pro, which offers a holistic approach to repair the signs of aging.